(Press-News.org) The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, announced the start of a multi-country study to better understand the burden of Human papillomavirus (HPV) among girls and women in low- and lower middle-income countries. This study received $14.99 million USD in funding from the Bill & Melinda Gates Foundation with $1 million USD co-funding from the Swedish government and will help inform intervention implementation and prioritization of research and development efforts that have the greatest potential public health impact.
The focus of this global HPV burden study will be on girls and women ages 9 to 50 in three South Asian countries and five sub-Saharan African countries that currently have no or limited data on HPV burden and have either not yet introduced HPV vaccines into national immunization programs or have had mixed success with uptake. The study also includes qualitative sub-studies to further understand how gender-related dynamics create barriers to HPV prevention, screening, and treatment services, further influencing HPV burden in girls and women.
Dr. Julia Lynch, IVI’s Cholera Program Director and HPV Study Team Lead, said: “Nearly all cases of cervical cancer are due to HPV infection. Less than 15% of girls and women worldwide are fully vaccinated and coverage is even lower in low- and middle-income countries. Through this global burden study, we hope to generate data that will inform effective strategies to prevent infection and ultimately introduce HPV vaccine into national programs, protecting the health of girls and women and reducing rates of cervical cancer.”
Prof. Deborah Watson-Jones, co-investigator and Professor of Clinical Epidemiology & International Health at the London School of Hygiene & Tropical Medicine (LSHTM), said: “HPV epidemiology and prevention in sub-Saharan Africa has been a focus of research for LSHTM for more than 15 years. We are proud to be part of this consortium and to work with IVI and our partners in the region on a critically important project that will provide up-to-date data that can inform future targeted intervention strategies for cervical cancer prevention that will improve the health of women in the continent.”
Dr. Anna Kågesten, co-investigator and Assistant Professor at Karolinska Institutet, said: “Gender inequality remains a barrier for women and girls to realize their sexual and reproductive health and rights globally. This study will help us unpack gender-related drivers such as social norms and stigma around young women’s sexuality, that shape their access to and uptake of HPV prevention, screening, and treatment services in different contexts.”
Collaborators on this study include investigators from LSHTM, who are part of the Single-Dose HPV Vaccine Evaluation Consortium along with Dr. Lynch, and investigators from the Department of Global Public Health at Karolinska Institutet. The team has completed regional workshops to ensure a harmonized study protocol across all eight countries, hosted in Nepal for the South Asian countries (Bangladesh, Nepal, and Pakistan) and Tanzania for the African countries (the Democratic Republic of the Congo, Ghana, Sierra Leone, Tanzania, and Zambia).
This is IVI’s second grant from the Bill & Melinda Gates Foundation to understand and remove barriers to HPV prevention and vaccination. IVI is also leading a study in partnership with the Ministry of Public Health of Thailand to demonstrate the effectiveness of a single dose of HPV, thereby making vaccination more accessible than the current two- or three-dose schedules.
###
About the International Vaccine Institute (IVI)
The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.
IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that is currently under assessment for WHO PQ.
IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden and Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, and Finland provide state funding. For more information, please visit https://www.ivi.int.
END
IVI launches global study to determine the burden of HPV among girls and women
2023-03-07
ELSE PRESS RELEASES FROM THIS DATE:
Novel porous materials are ideal for metal-air batteries, researchers report
2023-03-07
Sustainable energy solutions cannot be pulled out of thin air. However, combining air with metal and other frameworks may pave the way for environmentally friendly energy conversion and storage, according to a research team based in China.
They published their review of novel porous materials — called metal-organic frameworks (MOFs) and covalent organic frameworks (COFs) — and their potential to advance metal-air batteries on 03 March in Nano Research Energy.
The porous crystal material frameworks comprise various arrangements of bonded materials that can induce desired properties, including the ability to accelerate reactions between oxygen and metals ...
Novel biomimetic polypeptides activate tumor-infiltrating macrophages, offering hope for cancer therapy
2023-03-07
Macrophages are highly specialized cells of the immune system that help the body detect and fight deadly pathogens. In particular, M1-like macrophages detect and destroy tumor cells, and release protective chemokines such as interleukin (IL)-6 and tumor-necrosis factor α (TNF α), thus shielding the body from life-threatening pathologies like cancer. However, not all macrophages show anti-tumor potential. Certain types of macrophages, i.e., M2-like macrophages, promote tumor growth. Luckily, the desired macrophage phenotype—a set of traits resulting from the genetic makeup of the macrophage—can be activated by modulating the ...
AI accurately identifies normal and abnormal chest x-rays
2023-03-07
OAK BROOK, Ill. – An artificial intelligence (AI) tool can accurately identify normal and abnormal chest X-rays in a clinical setting, according to a study published in Radiology, a journal of the Radiological Society of North America (RSNA).
Chest X-rays are used to diagnose a wide variety of conditions to do with the heart and lungs. An abnormal chest X-ray can be an indication of a range of conditions, including cancer and chronic lung diseases.
An AI tool that can accurately differentiate between normal and abnormal chest X-rays would greatly alleviate the heavy workload experienced by radiologists globally.
“There is an exponentially growing demand for medical ...
Study: intraoperative 3-D imaging can improve accuracy of pedicle screw placement in spine surgery
2023-03-07
A study at Hospital for Special Surgery (HSS) found that intraoperative three-dimensional (3D) imaging was superior to two-dimensional radiographs in confirming the accuracy of pedicle screw placement during spine surgery. The research was presented today at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas.
Many spinal surgeries require the use of implants called pedicle screws to stabilize the spine. Precise positioning of these screws is critical for a successful outcome. “Two-dimensional biplanar radiographs [BPR] ...
Magnetically actuated quadruped soft microrobot toward gastric biopsy
2023-03-07
Recently, a research team from Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, proposed a bionic quadruped soft thin-film microrobot actuated by magnetic fields with a mass of only 41 mg, which promises to be applied to stomach examination and treatment. Researchers realized the multimodal locomotion control of the soft microrobot in magnetic fields and the grasping and transportation of micro-objects by the soft microrobot.
The new paper, published in Cyborg and Bionic System, details the process ...
Scientists observe “quasiparticles” in classical systems for the first time
2023-03-07
Starting with the emergence of quantum mechanics, the world of physics has been divided between classical and quantum physics. Classical physics deals with the motions of objects we typically see every day in the macroscopic world, while quantum physics explains the exotic behaviors of elementary particles in the microscopic world.
Many solids or liquids are composed of particles interacting with one another at close distances, which sometimes results in the rise of “quasiparticles.” Quasiparticles are long-lived excitations that behave effectively as weakly interacting particles. The idea of quasiparticles was introduced by the Soviet physicist Lev Landau in 1941, and ...
Slicing capacity-centered mode selection and resource optimization for network-assisted full-duplex cell-free distributed massive MIMO systems
2023-03-07
Network-assisted full-duplex (NAFD) systems enable uplink and downlink communications within the same time-frequency resources, so as to avoid the overhead of switching uplink/downlink modes. However, as the number of users and access points (APs) proliferated, mass access brings significant overhead in mode selection. In addition, the differentiated service demands among users also makes the effective utilization of resources difficult. Combined with network slicing technology, a slicing capacity-centered mode selection and resource optimization scheme is proposed. This scheme adopts a double-layer deep reinforcement ...
Do you see me? New study examines how women of colour experience invisibility in the workplace
2023-03-07
“As a Black woman, I’m invisible. They just erase your humanity. You don’t exist in front of them.” (Tessa, 33-year-old Black research assistant)
“It wasn’t about disliking what I did or being judgmental of what I did. It was a different kind of problem, to not be acknowledged. They didn’t care. There was no curiosity. They didn’t give a f***. We were invisible.” (Brinda, 30-year-old South Asian consultant)
Invisibility is a salient and recurring experience of mistreatment for women of colour working in traditionally white and male professions, two ...
Muffins that could be good for your health
2023-03-07
Love muffins? We’re talking about a tasty, fluffy muffin that has no artificial additives and that simultaneously contains lots of beneficial nutrients. As remarkable as it might sound, a recently published study led describes the development of just such a new muffin in the journal Foods.
From muffins to functional food
The new super muffin has been named Roselle, because it contains calyx extract from the tropical plant Hibiscus sabdariffa, which is often referred to by the same name.
[caption id="attachment_79738" align="aligncenter" width="559"] Here's a look at the different formulations that researchers tested. Photo: Screenshot from Food ...
Join us at #DiscoverBMB 2023 for the latest molecular life sciences research
2023-03-07
Will AI drive the next biomedical revolution? Why is RNA so powerful? What can we learn from studying bias? You’ll get the answers to these questions and more at Discover BMB, the annual meeting of the American Society for Biochemistry and Molecular Biology, to be held March 25–28 in Seattle.
Reporters are invited to register for a complimentary press pass to attend #DiscoverBMB in Seattle or to access press materials electronically.
This year’s #DiscoverBMB program features leading ...